Eleanor Laise is a healthcare reporter for MarketWatch and is based in Washington.
Novo Nordisk NVO, +2.67% on Friday boosted its full-year 2023 profit and sales outlook, reflecting heightened expectations for Ozempic and Wegovy sales. The company now projects full-year sales growth of 32% to 38%, up from 27% to 33% previously, and operating profit growth of 40% to 46%, up from 31% to 37% previously. The brighter outlook factors in higher expected U.S.
Ozempic sales volumes as well as gross-to-net sales adjustments for both Ozempic and Wegovy in the U.S., the company said. In the first nine months of 2023, sales growth at constant exchange rates was 33%, while operating profit growth clocked in at 37%, Novo Nordisk said Friday. Novo Nordisk’s American depositary receipts gained 2.2% premarket Friday and are up 48% in the year to date, while the S&P 500 SPX, +0.32% is up 13.3%.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Novo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surgeNovo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surge
Les mer »
Novo Nordisk warns online offers of fake Ozempic, Wegovy are risingNovo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Les mer »
Novo Nordisk: Online Ozempic, Wegovy Fakes RisingNovo Nordisk warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.'Novo Nordisk has seen a significant increase...
Les mer »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Les mer »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and moreThese are some of the stocks posting the largest moves midday.
Les mer »
DaVita plays down Ozempic’s potential in treating kidney diseaseDialysis company’s stock falls again after Novo Nordisk said Ozempic was successful in treating kidney failure in a trial
Les mer »